These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25998620)

  • 1. The Role of TLR4 in Chemotherapy-Driven Metastasis.
    Ran S
    Cancer Res; 2015 Jun; 75(12):2405-10. PubMed ID: 25998620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner.
    Volk-Draper L; Hall K; Griggs C; Rajput S; Kohio P; DeNardo D; Ran S
    Cancer Res; 2014 Oct; 74(19):5421-34. PubMed ID: 25274031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphatic endothelial progenitors originate from plastic myeloid cells activated by toll-like receptor-4.
    Volk-Draper LD; Hall KL; Wilber AC; Ran S
    PLoS One; 2017; 12(6):e0179257. PubMed ID: 28598999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis.
    Hsu RY; Chan CH; Spicer JD; Rousseau MC; Giannias B; Rousseau S; Ferri LE
    Cancer Res; 2011 Mar; 71(5):1989-98. PubMed ID: 21363926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toll-like receptor 4 and breast cancer: an updated systematic review.
    Khademalhosseini M; Arababadi MK
    Breast Cancer; 2019 May; 26(3):265-271. PubMed ID: 30543015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ephrin-A1 expression induced by S100A8 is mediated by the toll-like receptor 4.
    Ieguchi K; Omori T; Komatsu A; Tomita T; Deguchi A; Maru Y
    Biochem Biophys Res Commun; 2013 Nov; 440(4):623-9. PubMed ID: 24103748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway.
    Chen R; Alvero AB; Silasi DA; Mor G
    Am J Reprod Immunol; 2007 Feb; 57(2):93-107. PubMed ID: 17217363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCL10 conditions alveolar macrophages within the premetastatic niche to promote metastasis.
    Shang C; Sun Y; Wang Y; Shi H; Han X; Mo Y; Wang D; Ke Y; Zeng X
    Cancer Lett; 2022 Jul; 537():215667. PubMed ID: 35398531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triggering of Toll-like receptor 4 on metastatic breast cancer cells promotes αvβ3-mediated adhesion and invasive migration.
    Liao SJ; Zhou YH; Yuan Y; Li D; Wu FH; Wang Q; Zhu JH; Yan B; Wei JJ; Zhang GM; Feng ZH
    Breast Cancer Res Treat; 2012 Jun; 133(3):853-63. PubMed ID: 22042369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.
    Hua D; Liu MY; Cheng ZD; Qin XJ; Zhang HM; Chen Y; Qin GJ; Liang G; Li JN; Han XF; Liu DX
    Mol Immunol; 2009 Sep; 46(15):2876-84. PubMed ID: 19643479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of toll-like receptor 4 (TLR4) in cancer progression: A possible therapeutic target?
    Kashani B; Zandi Z; Pourbagheri-Sigaroodi A; Bashash D; Ghaffari SH
    J Cell Physiol; 2021 Jun; 236(6):4121-4137. PubMed ID: 33230811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelets promote tumour metastasis via interaction between TLR4 and tumour cell-released high-mobility group box1 protein.
    Yu LX; Yan L; Yang W; Wu FQ; Ling Y; Chen SZ; Tang L; Tan YX; Cao D; Wu MC; Yan HX; Wang HY
    Nat Commun; 2014 Oct; 5():5256. PubMed ID: 25348021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PFKFB3 potentially contributes to paclitaxel resistance in breast cancer cells through TLR4 activation by stimulating lactate production.
    Ge X; Cao Z; Gu Y; Wang F; Li J; Han M; Xia W; Yu Z; Lyu P
    Cell Mol Biol (Noisy-le-grand); 2016 May; 62(6):119-25. PubMed ID: 27262815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Premetastatic milieu explained by TLR4 agonist-mediated homeostatic inflammation.
    Maru Y
    Cell Mol Immunol; 2010 Mar; 7(2):94-9. PubMed ID: 20140009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of myeloid differentiation primary response 88 and Toll-like receptor 4 in breast cancer patients.
    Ma FJ; Liu ZB; Hu X; Ling H; Li S; Wu J; Shao ZM
    PLoS One; 2014; 9(10):e111639. PubMed ID: 25360699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.
    Garay RP; Viens P; Bauer J; Normier G; Bardou M; Jeannin JF; Chiavaroli C
    Eur J Pharmacol; 2007 Jun; 563(1-3):1-17. PubMed ID: 17383632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.
    Apetoh L; Ghiringhelli F; Tesniere A; Criollo A; Ortiz C; Lidereau R; Mariette C; Chaput N; Mira JP; Delaloge S; André F; Tursz T; Kroemer G; Zitvogel L
    Immunol Rev; 2007 Dec; 220():47-59. PubMed ID: 17979839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells.
    Zhang Y; Wang Y; Yuan J; Qin W; Liu F; Wang F; Zhang G; Yang X
    Cell Biol Toxicol; 2012 Aug; 28(4):269-77. PubMed ID: 22648782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of toll-like receptor 4 inhibits human NSCLC cancer cell growth and inflammatory cytokine secretion in vitro and in vivo.
    Li D; Jin Y; Sun Y; Lei J; Liu C
    Int J Oncol; 2014 Aug; 45(2):813-21. PubMed ID: 24889928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eritoran inhibits S100A8-mediated TLR4/MD-2 activation and tumor growth by changing the immune microenvironment.
    Deguchi A; Tomita T; Ohto U; Takemura K; Kitao A; Akashi-Takamura S; Miyake K; Maru Y
    Oncogene; 2016 Mar; 35(11):1445-56. PubMed ID: 26165843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.